Oruka Therapeutics, Inc.
ORKANASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $4.64B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $25.11$115.52
- Volume (live)
- -
- Avg. volume (3M)
- 975.98K
Oruka Therapeutics (ORKA) Stock Price & Financial Analysis
Oruka Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $70.50 - $74.26 |
|---|---|
| 52-Week High | $115.52 |
| 52-Week Low | $25.11 |
| Open | $73.75 |
| Volume (last close) | 1.38M |
| Average Volume (3M) | 975.98K |
| 50-Day MA | $93.57 |
|---|---|
| 200-Day MA | $65.89 |
| 1-Year Change | +168.81% |
| Market Cap | 4.64B |
|---|---|
| Shares Outstanding | 62.87M |
| Price to Book (P/B) | 4.18 |
| EV/EBITDA | -30.91 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Last Dividend Ex-Date | Aug 29, 2024 |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Oruka Therapeutics at a Glance
As of the Oct 16, 2026 close, Oruka Therapeutics (ORKA) has a market capitalization of $4.64B.
As of its latest reported balance sheet, it holds $268.47M in cash and securities against $2.55M of debt, a net cash position of $265.92M.
Oruka Therapeutics does not currently pay a dividend.
The share price is up 168.8% over the past year. At $71.93 (the Oct 16, 2026 close) it sits within its 52-week range of $25.11 to $115.52, above its 200-day moving average of $65.89.
Based on 12 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $154.50, 114.8% above the Oct 16, 2026 close.
Frequently Asked Questions About Oruka Therapeutics
What is the current stock price for ORKA?
As of the Oct 16, 2026 close, ORKA stock trades at $71.93. The 52-week range is $25.11–$115.52, with a day range of $70.50–$74.26.
What is the P/E ratio for ORKA?
The P/E ratio (Price-to-Earnings) for ORKA is shown in the Key Statistics section. This valuation metric helps compare Oruka Therapeutics, Inc. to industry peers.
Does ORKA pay dividends?
Oruka Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for ORKA?
Based on ratings from 12 professional analysts over the last 90 days, the consensus for ORKA is Buy. The average 12-month price target is $154.50, a 114.8% upside from the Oct 16, 2026 close of $71.93.
What is the market cap of ORKA?
As of the Oct 16, 2026 close, Oruka Therapeutics's market capitalization is $4.52B, classifying it as a mid-cap company. Oruka Therapeutics operates in the Healthcare sector within the Biotechnology industry.